NCT00927966View on ClinicalTrials.gov

RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms

PHASE1CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

SarcomaSolid Tumor

Interventions

DRUG

RAD001

Taken orally once a day.

DRUG

CP-751,871

Given intravenously on Day 1 of a 21-day cycle

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (2)

All Listed Sponsors

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Novartis

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

Suzanne George, MD

OTHER